Annette McWilliams
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Annette McWilliams has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Stephen Lam
Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, Canada
6 shared publications - Henry M. Marshall
University of Queensland Thoracic Research Centre and Department of Thoracic Medicine, The Prince Charles Hospital, Chermside, Queensland, Australia
5 shared publications - Emily Stone
Department of Thoracic Medicine and Lung Transplantation, St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia; School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Kensington, New South Wales, Australia
4 shared publications - Fraser Brims
Curtin Medical School, Curtin University, Perth, Australia
4 shared publications - Martin Carl Tammemagi
Brock University, St. Catharines, Ontario, Canada
3 shared publications - Nicole Marion Rankin
Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia; Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia
3 shared publications
Latest Publications
- Open Access
- 26 September 2026
- Published by Elsevier in Australian and New Zealand Journal of Public Health
- Vol. 50 (5) , 100594
Embedding smoking cessation into lung cancer screening: Priorities of national expert stakeholders in Australia using a modified nominal group technique
- 26 September 2026
- Published by Elsevier in Australian and New Zealand Journal of Public Health
- Vol. 50 (5) , 100594
Open AccessEmbedding smoking cessation into lung cancer screening: Priorities of national expert stakeholders in Australia using a modified nominal group technique
- Open Access
- 27 February 2026
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 70 (3) , 294-303
Rationale for the Nodule Management Protocol of the Australian National Lung Cancer Screening Program
In July 2022, the Australian Medical Services Advisory Committee (MSAC) recommended the establishment of an Australian NLCSP (National Lung Cancer Screening Program), using low‐dose computed tomography (LDCT) for the early detection of lung cancer in asymptomatic high‐risk individuals. MSAC's recommendations for the NLCSP included core requirements as follows: (i) routine biennial screening, (ii) use of the PanCan risk prediction model for reporting baseline LDCT, and (iii) the use of the most recent version of Lung‐RADS for reporting follow‐up LDCT. Necessary adaptations were made to incorporate these requirements, resulting in a bespoke protocol for the Australian context. This article summarises the rationale and development of the NLCSP Nodule Management Protocol.
- 27 February 2026
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 70 (3) , 294-303
Open AccessRationale for the Nodule Management Protocol of the Australian National Lung Cancer Screening Program
In July 2022, the Australian Medical Services Advisory Committee (MSAC) recommended the establishment of an Australian NLCSP (National Lung Cancer Screening Program), using low‐dose computed tomography (LDCT) for the early detection of lung cancer in asymptomatic high‐risk individuals. MSAC's recommendations for the NLCSP included core requirements as follows: (i) routine biennial screening, (ii) use of the PanCan risk prediction model for reporting baseline LDCT, and (iii) the use of the most recent version of Lung‐RADS for reporting follow‐up LDCT. Necessary adaptations were made to incorporate these requirements, resulting in a bespoke protocol for the Australian context. This article summarises the rationale and development of the NLCSP Nodule Management Protocol.
- Open Access
- 18 January 2026
- Published by Wiley in Health Expectations
- Vol. 29 (1) , e70557
Engaging Culturally and Linguistically Diverse Communities to Prepare for Lung Cancer Screening Implementation in Australia: A Qualitative Focus Group Study
Introduction: Lung cancer is the number one cause of cancer death worldwide, including in Australia, where more than 15,000 cases were diagnosed in 2024. The Australian National Lung Cancer Screening Programme commenced in July 2025. Unique barriers to participation in existing cancer screening programmes exist for culturally and linguistically diverse (CALD) communities. Little Australian research has engaged these communities to gauge their acceptability and readiness for the implementation of lung cancer screening (LCS). The aims were to identify barriers and enablers to LCS implementation and determine views about LCS acceptability and feasibility. Methods: Community‐based participatory research principles were used to collaboratively engage CALD stakeholders. The research team worked with highly experienced programme managers, multicultural health workers and bilingual facilitators/translators (‘leaders’) who provide support and education to Arabic‐speaking/Lebanese, Macedonian, Vietnamese and Italian communities. Leaders used culturally appropriate methods to recruit participants and deliver focus groups. Verbatim transcripts were analysed using a coding framework based on the Health Equity Implementation Framework. Results: Seven focus groups were conducted either face to face ( n = 5) or online ( n = 2) with 57 participants across New South Wales, Australia. Six groups were delivered in community languages. LCS was generally perceived as acceptable across all focus groups. Key enablers towards engagement were understanding the importance of screening for early detection, provision of interpreters and easily accessible locations. Key barriers were financial and language barriers, poor experiences with other cancer screening programmes, concerns about tobacco‐related eligibility criteria and cancer‐related stigma. Conclusions: This qualitative study provides crucial foundational evidence from four culturally diverse Australian communities about barriers and enablers to inform Programme implementation. The findings are highly relevant to other jurisdictions that may be preparing for LCS implementation or need to modify programmes to engage culturally diverse populations to screen. Patient or Public Contribution: Members of the public were directly involved as participants in this research. Multicultural health workers and bilingual facilitators/interpreters who work with CALD communities were involved in all phases of the study design and implementation, including recruitment, development of semi‐structured focus group guide, focus group facilitation and reviewing the manuscript.
- 18 January 2026
- Published by Wiley in Health Expectations
- Vol. 29 (1) , e70557
Open AccessEngaging Culturally and Linguistically Diverse Communities to Prepare for Lung Cancer Screening Implementation in Australia: A Qualitative Focus Group Study
Introduction: Lung cancer is the number one cause of cancer death worldwide, including in Australia, where more than 15,000 cases were diagnosed in 2024. The Australian National Lung Cancer Screening Programme commenced in July 2025. Unique barriers to participation in existing cancer screening programmes exist for culturally and linguistically diverse (CALD) communities. Little Australian research has engaged these communities to gauge their acceptability and readiness for the implementation of lung cancer screening (LCS). The aims were to identify barriers and enablers to LCS implementation and determine views about LCS acceptability and feasibility. Methods: Community‐based participatory research principles were used to collaboratively engage CALD stakeholders. The research team worked with highly experienced programme managers, multicultural health workers and bilingual facilitators/translators (‘leaders’) who provide support and education to Arabic‐speaking/Lebanese, Macedonian, Vietnamese and Italian communities. Leaders used culturally appropriate methods to recruit participants and deliver focus groups. Verbatim transcripts were analysed using a coding framework based on the Health Equity Implementation Framework. Results: Seven focus groups were conducted either face to face ( n = 5) or online ( n = 2) with 57 participants across New South Wales, Australia. Six groups were delivered in community languages. LCS was generally perceived as acceptable across all focus groups. Key enablers towards engagement were understanding the importance of screening for early detection, provision of interpreters and easily accessible locations. Key barriers were financial and language barriers, poor experiences with other cancer screening programmes, concerns about tobacco‐related eligibility criteria and cancer‐related stigma. Conclusions: This qualitative study provides crucial foundational evidence from four culturally diverse Australian communities about barriers and enablers to inform Programme implementation. The findings are highly relevant to other jurisdictions that may be preparing for LCS implementation or need to modify programmes to engage culturally diverse populations to screen. Patient or Public Contribution: Members of the public were directly involved as participants in this research. Multicultural health workers and bilingual facilitators/interpreters who work with CALD communities were involved in all phases of the study design and implementation, including recruitment, development of semi‐structured focus group guide, focus group facilitation and reviewing the manuscript.
- Open Access
- 29 May 2025
- Published by Wiley in Respirology
- Vol. 30 (7) , 558-573
The TSANZ Practical Guide for Clinicians in the Management of Screen‐ and Incidentally‐Detected Nodules
The increasing adoption of lung cancer screening programs and advancements in imaging technologies has significantly increased the detection of pulmonary nodules, both incidentally and through screening. This document provides a comprehensive guide for clinicians to address the complexities of managing indeterminate pulmonary nodules (IPNs), emphasising person‐centred and multidisciplinary care. IPNs are categorised based on size and morphology, with specific guidelines for malignancy risk stratification, diagnostic evaluation, and follow‐up. Dedicated lung nodule evaluation teams (LNETs) and nodule multidisciplinary meetings (MDMs) play a critical role in ensuring guideline adherence, streamlining the diagnostic pathway, reducing unnecessary investigations, and improving outcomes. Structured IPN programs have demonstrated benefits in early lung cancer detection, improved detection of early‐stage lung cancer, and reduced delays to treatment initiation. Effective management strategies include use of standardised reporting templates, utilising validated risk models such as the PanCan malignancy risk model and agreed protocols for follow up of IPNs. This document highlights the importance of accessing prior imaging to assess for growth and accounting for technical differences between computed tomography (CT) scans. Any nodule considered to be growing requires discussion at a nodule MDM with decision to act for tissue biopsy as appropriate. A nodule MDM will assist in optimising the safest and most efficient biopsy techniques based on nodule characteristics and risk profile. By integrating multidisciplinary expertise and adhering to evidence‐based protocols, services can improve the timely diagnosis and management of IPNs, minimise over‐investigation, reduce chance of overdiagnosis and ultimately enhance patient outcomes and lung cancer survival.
- 29 May 2025
- Published by Wiley in Respirology
- Vol. 30 (7) , 558-573
Open AccessThe TSANZ Practical Guide for Clinicians in the Management of Screen‐ and Incidentally‐Detected Nodules
The increasing adoption of lung cancer screening programs and advancements in imaging technologies has significantly increased the detection of pulmonary nodules, both incidentally and through screening. This document provides a comprehensive guide for clinicians to address the complexities of managing indeterminate pulmonary nodules (IPNs), emphasising person‐centred and multidisciplinary care. IPNs are categorised based on size and morphology, with specific guidelines for malignancy risk stratification, diagnostic evaluation, and follow‐up. Dedicated lung nodule evaluation teams (LNETs) and nodule multidisciplinary meetings (MDMs) play a critical role in ensuring guideline adherence, streamlining the diagnostic pathway, reducing unnecessary investigations, and improving outcomes. Structured IPN programs have demonstrated benefits in early lung cancer detection, improved detection of early‐stage lung cancer, and reduced delays to treatment initiation. Effective management strategies include use of standardised reporting templates, utilising validated risk models such as the PanCan malignancy risk model and agreed protocols for follow up of IPNs. This document highlights the importance of accessing prior imaging to assess for growth and accounting for technical differences between computed tomography (CT) scans. Any nodule considered to be growing requires discussion at a nodule MDM with decision to act for tissue biopsy as appropriate. A nodule MDM will assist in optimising the safest and most efficient biopsy techniques based on nodule characteristics and risk profile. By integrating multidisciplinary expertise and adhering to evidence‐based protocols, services can improve the timely diagnosis and management of IPNs, minimise over‐investigation, reduce chance of overdiagnosis and ultimately enhance patient outcomes and lung cancer survival.
- Open Access
- 24 September 2024
- Published by Wiley in Respirology
- Vol. 30 (1) , 62-69
Coronary artery calcification detected on low‐dose computed tomography in high‐risk participants of an Australian lung cancer screening program: A prospective observational study
Background and Objectives: Coronary artery calcification (CAC) is a frequent additional finding on lung cancer screening (LCS) low‐dose computed tomography (LDCT). Cardiovascular disease (CVD) is a major cause of death in LCS participants. We aimed to describe prevalence of incidental CAC detected on LDCT in LCS participants without prior history of coronary artery disease (CAD), evaluate their CVD risk and describe subsequent investigation and management. Methods: Prospective observational nested cohort study including all participants enrolled at a single Australian site of the International Lung Screen Trial. Baseline LDCTs were reviewed for CAC, and subsequent information collected regarding cardiovascular health. 5‐year CVD risk was calculated using the AusCVD risk calculator. Results: 55% (226/408) of participants had CAC on LDCT and no prior history of CAD, including 23% with moderate–severe CAC. Mean age of participants with CAC was 65 years, 68% were male. 53% were currently smoking. Majority were high risk (51%) or intermediate risk (32%) of a cardiovascular event in 5 years. 21% of participants were re‐stratified to a higher CVD risk group when CAC detected on LCS was incorporated. Only 10% of participants with CAC received lifestyle advice (only 3% currently smoking received smoking cessation advice). 80% of participants at high‐risk did not meet guideline recommendations, with 47% of this group remaining without cholesterol lowering therapy. Conclusion: LCS with LDCT offers the potential to identify and communicate CVD risk in this population. This may improve health outcomes for high‐risk LCS participants and further personalize management once screening results are known.
- 24 September 2024
- Published by Wiley in Respirology
- Vol. 30 (1) , 62-69
Open AccessCoronary artery calcification detected on low‐dose computed tomography in high‐risk participants of an Australian lung cancer screening program: A prospective observational study
Background and Objectives: Coronary artery calcification (CAC) is a frequent additional finding on lung cancer screening (LCS) low‐dose computed tomography (LDCT). Cardiovascular disease (CVD) is a major cause of death in LCS participants. We aimed to describe prevalence of incidental CAC detected on LDCT in LCS participants without prior history of coronary artery disease (CAD), evaluate their CVD risk and describe subsequent investigation and management. Methods: Prospective observational nested cohort study including all participants enrolled at a single Australian site of the International Lung Screen Trial. Baseline LDCTs were reviewed for CAC, and subsequent information collected regarding cardiovascular health. 5‐year CVD risk was calculated using the AusCVD risk calculator. Results: 55% (226/408) of participants had CAC on LDCT and no prior history of CAD, including 23% with moderate–severe CAC. Mean age of participants with CAC was 65 years, 68% were male. 53% were currently smoking. Majority were high risk (51%) or intermediate risk (32%) of a cardiovascular event in 5 years. 21% of participants were re‐stratified to a higher CVD risk group when CAC detected on LCS was incorporated. Only 10% of participants with CAC received lifestyle advice (only 3% currently smoking received smoking cessation advice). 80% of participants at high‐risk did not meet guideline recommendations, with 47% of this group remaining without cholesterol lowering therapy. Conclusion: LCS with LDCT offers the potential to identify and communicate CVD risk in this population. This may improve health outcomes for high‐risk LCS participants and further personalize management once screening results are known.
- Open Access
- 13 August 2024
- Published by Wiley in Respirology
- Vol. 29 (12) , 1085-1094
Lung cancer (internet‐based) Delphi (LUCiD): A modified eDelphi consensus process to establish Australasian clinical quality indicators for thoracic cancer
Background and Objective: Approximately 16,000 new cases of lung cancer are diagnosed each year in Australia and Aotearoa New Zealand, and it is the leading cause of cancer death in the region. Unwarranted variation in lung cancer care and outcomes has been described for many years, although clinical quality indicators to facilitate benchmarking across Australasia have not been established. The purpose of this study was to establish clinical quality indicators applicable to lung and other thoracic cancers across Australia and Aotearoa New Zealand.Methods: Following a literature review, a modified three round eDelphi consensus process was completed between October 2022 and June 2023. Participants included clinicians from all relevant disciplines, patient advocates, researchers and other stakeholders, with representatives from all Australian states and territories and Aotearoa New Zealand. Consensus was set at a threshold of 70%, with the first two rounds conducted as online surveys, and the final round held as a hybrid in person and virtual consensus meeting.Results: The literature review identified 422 international thoracic oncology indicators, and a total of 71 indicators were evaluated over the course of the Delphi consensus. Ultimately, 27 clinical quality indicators reached consensus, covering the continuum of thoracic oncologic care from diagnosis to first line treatment. Indicators benchmarking supportive care were poorly represented. Attendant numeric quality standards were developed to facilitate benchmarking.Conclusion: Twenty‐seven clinical quality indicators relevant to thoracic oncology care in Australasia were developed. Real world implementation will now be explored utilizing a prospective dataset collected across Australia.
- 13 August 2024
- Published by Wiley in Respirology
- Vol. 29 (12) , 1085-1094
Open AccessLung cancer (internet‐based) Delphi (LUCiD): A modified eDelphi consensus process to establish Australasian clinical quality indicators for thoracic cancer
Background and Objective: Approximately 16,000 new cases of lung cancer are diagnosed each year in Australia and Aotearoa New Zealand, and it is the leading cause of cancer death in the region. Unwarranted variation in lung cancer care and outcomes has been described for many years, although clinical quality indicators to facilitate benchmarking across Australasia have not been established. The purpose of this study was to establish clinical quality indicators applicable to lung and other thoracic cancers across Australia and Aotearoa New Zealand.Methods: Following a literature review, a modified three round eDelphi consensus process was completed between October 2022 and June 2023. Participants included clinicians from all relevant disciplines, patient advocates, researchers and other stakeholders, with representatives from all Australian states and territories and Aotearoa New Zealand. Consensus was set at a threshold of 70%, with the first two rounds conducted as online surveys, and the final round held as a hybrid in person and virtual consensus meeting.Results: The literature review identified 422 international thoracic oncology indicators, and a total of 71 indicators were evaluated over the course of the Delphi consensus. Ultimately, 27 clinical quality indicators reached consensus, covering the continuum of thoracic oncologic care from diagnosis to first line treatment. Indicators benchmarking supportive care were poorly represented. Attendant numeric quality standards were developed to facilitate benchmarking.Conclusion: Twenty‐seven clinical quality indicators relevant to thoracic oncology care in Australasia were developed. Real world implementation will now be explored utilizing a prospective dataset collected across Australia.
- Open Access
Estimates of the eligible population for Australia’s targeted National Lung Cancer Screening Program, 2025-2030
Australia’s National Lung Cancer Screening Program will commence in July 2025, targeted at individuals aged 50-70 years with a 30 pack-year smoking history, who either currently smoke or have quit within the last 10 years. We forecasted the number of screening-eligible individuals over the first 5 years of the program using data from the 2019 National Drug Strategy Household Survey, and the 2022 Australian Bureau of Statistics population projections. Multiple imputation integrated with predictive modelling of future or unmeasured smoking characteristics was used to address missing data and simultaneously, to project individuals’ smoking histories to 2030. In 2025, 930,500 (95% prediction interval 852,200-1,019,000) individuals were estimated to be eligible, with the number meeting the criteria declining slightly over the years 2025-2030 in all Australian jurisdictions. Overall, 26-30% of those eligible will have quit smoking, and 70-74% will currently smoke. These estimates can be used in resource planning and as an indicative denominator to track participation rates for the program over time.
Open AccessEstimates of the eligible population for Australia’s targeted National Lung Cancer Screening Program, 2025-2030
Australia’s National Lung Cancer Screening Program will commence in July 2025, targeted at individuals aged 50-70 years with a 30 pack-year smoking history, who either currently smoke or have quit within the last 10 years. We forecasted the number of screening-eligible individuals over the first 5 years of the program using data from the 2019 National Drug Strategy Household Survey, and the 2022 Australian Bureau of Statistics population projections. Multiple imputation integrated with predictive modelling of future or unmeasured smoking characteristics was used to address missing data and simultaneously, to project individuals’ smoking histories to 2030. In 2025, 930,500 (95% prediction interval 852,200-1,019,000) individuals were estimated to be eligible, with the number meeting the criteria declining slightly over the years 2025-2030 in all Australian jurisdictions. Overall, 26-30% of those eligible will have quit smoking, and 70-74% will currently smoke. These estimates can be used in resource planning and as an indicative denominator to track participation rates for the program over time.
- Open Access
- 16 November 2020
- Published by Wiley in Respirology
- Vol. 25 (S2) , 5-23
Lung cancer screening implementation: Complexities and priorities
Lung cancer is the number one cause of cancer death worldwide. The benefits of lung cancer screening to reduce mortality and detect early‐stage disease are no longer in any doubt based on the results of two landmark trials using LDCT. Lung cancer screening has been implemented in the US and South Korea and is under consideration by other communities. Successful translation of demonstrated research outcomes into the routine clinical setting requires careful implementation and co‐ordinated input from multiple stakeholders. Implementation aspects may be specific to different healthcare settings. Important knowledge gaps remain, which must be addressed in order to optimize screening benefits and minimize screening harms. Lung cancer screening differs from all other cancer screening programmes as lung cancer risk is driven by smoking, a highly stigmatized behaviour. Stigma, along with other factors, can impact smokers' engagement with screening, meaning that smokers are generally ‘hard to reach’. This review considers critical points along the patient journey. The first steps include selecting a risk threshold at which to screen, successfully engaging the target population and maximizing screening uptake. We review barriers to smoker engagement in lung and other cancer screening programmes. Recruitment strategies used in trials and real‐world (clinical) programmes and associated screening uptake are reviewed. To aid cross‐study comparisons, we propose a standardized nomenclature for recording and calculating recruitment outcomes. Once participants have engaged with the screening programme, we discuss programme components that are critical to maximize net benefit. A whole‐of‐programme approach is required including a standardized and multidisciplinary approach to pulmonary nodule management, incorporating probabilistic nodule risk assessment and longitudinal volumetric analysis, to reduce unnecessary downstream investigations and surgery; the integration of smoking cessation; and identification and intervention for other tobacco related diseases, such as coronary artery calcification and chronic obstructive pulmonary disease. National support, integrated with tobacco control programmes, and with appropriate funding, accreditation, data collection, quality assurance and reporting mechanisms will enhance lung cancer screening programme success and reduce the risks associated with opportunistic, ad hoc screening. Finally, implementation research must play a greater role in informing policy change about targeted LDCT screening programmes.
- 16 November 2020
- Published by Wiley in Respirology
- Vol. 25 (S2) , 5-23
Open AccessLung cancer screening implementation: Complexities and priorities
Lung cancer is the number one cause of cancer death worldwide. The benefits of lung cancer screening to reduce mortality and detect early‐stage disease are no longer in any doubt based on the results of two landmark trials using LDCT. Lung cancer screening has been implemented in the US and South Korea and is under consideration by other communities. Successful translation of demonstrated research outcomes into the routine clinical setting requires careful implementation and co‐ordinated input from multiple stakeholders. Implementation aspects may be specific to different healthcare settings. Important knowledge gaps remain, which must be addressed in order to optimize screening benefits and minimize screening harms. Lung cancer screening differs from all other cancer screening programmes as lung cancer risk is driven by smoking, a highly stigmatized behaviour. Stigma, along with other factors, can impact smokers' engagement with screening, meaning that smokers are generally ‘hard to reach’. This review considers critical points along the patient journey. The first steps include selecting a risk threshold at which to screen, successfully engaging the target population and maximizing screening uptake. We review barriers to smoker engagement in lung and other cancer screening programmes. Recruitment strategies used in trials and real‐world (clinical) programmes and associated screening uptake are reviewed. To aid cross‐study comparisons, we propose a standardized nomenclature for recording and calculating recruitment outcomes. Once participants have engaged with the screening programme, we discuss programme components that are critical to maximize net benefit. A whole‐of‐programme approach is required including a standardized and multidisciplinary approach to pulmonary nodule management, incorporating probabilistic nodule risk assessment and longitudinal volumetric analysis, to reduce unnecessary downstream investigations and surgery; the integration of smoking cessation; and identification and intervention for other tobacco related diseases, such as coronary artery calcification and chronic obstructive pulmonary disease. National support, integrated with tobacco control programmes, and with appropriate funding, accreditation, data collection, quality assurance and reporting mechanisms will enhance lung cancer screening programme success and reduce the risks associated with opportunistic, ad hoc screening. Finally, implementation research must play a greater role in informing policy change about targeted LDCT screening programmes.